BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 23918698)

  • 1. Second study on valsartan is threatened with retraction over alleged data manipulation.
    Mahony C
    BMJ; 2013 Aug; 347():f4920. PubMed ID: 23918698
    [No Abstract]   [Full Text] [Related]  

  • 2. Valsartan-induced drug eruption followed by CD30+ pseudolymphomatous eruption.
    Sawada Y; Yoshiki R; Kawakami C; Fukamachi S; Sugita K; Nakamura M; Tokura Y
    Acta Derm Venereol; 2010 Sep; 90(5):521-2. PubMed ID: 20814632
    [No Abstract]   [Full Text] [Related]  

  • 3. Exanthematous drug eruption due to valsartan.
    Ozturk G; Turk BG; Senturk B; Turkmen M; Kandiloglu G
    Cutan Ocul Toxicol; 2012 Dec; 31(4):335-7. PubMed ID: 22257082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lithium intoxication after valsartan treatment.
    Su YP; Chang CJ; Hwang TJ
    Psychiatry Clin Neurosci; 2007 Apr; 61(2):204. PubMed ID: 17362443
    [No Abstract]   [Full Text] [Related]  

  • 5. Linear lichenoid drug eruption induced by valsartan.
    Gencoglan G; Ceylan C; Kazandi AC
    Clin Exp Dermatol; 2009 Oct; 34(7):e334-5. PubMed ID: 19456765
    [No Abstract]   [Full Text] [Related]  

  • 6. Aliskiren/valsartan (Valturna) for hypertension.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):94-5. PubMed ID: 20224524
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin receptor blockers and myocardial infarction.
    Verma S; Strauss M
    BMJ; 2004 Nov; 329(7477):1248-9. PubMed ID: 15564232
    [No Abstract]   [Full Text] [Related]  

  • 8. Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect.
    McAdams MA; Governale LA; Swartz L; Hammad TA; Dal Pan GJ
    Pharmacoepidemiol Drug Saf; 2008 Sep; 17(9):882-9. PubMed ID: 18636418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Angioedema and urticarial reaction induced by valsartan].
    de la Serna Higuera C
    Med Clin (Barc); 2000 Apr; 114(15):599. PubMed ID: 10846683
    [No Abstract]   [Full Text] [Related]  

  • 10. [New effective dosage of valsartan. High dosage--effective against high blood pressure].
    MMW Fortschr Med; 2007 Nov; 149(46):52-3. PubMed ID: 18069195
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin receptor blockers and myocardial infarction: the importance of dosage.
    Sarzani R; Dessì-Fulgheri P
    J Hypertens; 2006 Aug; 24(8):1679-81; author reply 1681-2. PubMed ID: 16877973
    [No Abstract]   [Full Text] [Related]  

  • 12. Valsartan. Just a second-line antihypertensive drug.
    Can Fam Physician; 1999 Nov; 45():2626-8, 2630-3. PubMed ID: 10587770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acute renal failure and hypertension].
    Bellido D; Sánchez de la Nieta MD; Vozmediano C; Oteros R; Zarca MA; Nieto J; Rivera F
    Nefrologia; 2005; 25(5):563-7. PubMed ID: 16392308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of valsartan-induced pneumonitis with marked elevation of serum KL-6].
    Takakura A; Kubota M; Otani S; Katono K; Yamamoto M; Masuda N
    Nihon Kokyuki Gakkai Zasshi; 2011 Jul; 49(7):523-7. PubMed ID: 21842690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fetal toxicity of angiotensin-II-receptor inhibitors. Case report].
    Roger N; Popovic I; Madelenat P; Mahieu-Caputo D
    Gynecol Obstet Fertil; 2007 Jun; 35(6):556-60. PubMed ID: 17544313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two amlodipine/ARB combinations for hypertension.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):101-2. PubMed ID: 18084152
    [No Abstract]   [Full Text] [Related]  

  • 17. [Scientific evidence--applied in routine general practice. Successful decrease in pressure and risk].
    MMW Fortschr Med; 2006 May; 148(18):42-3. PubMed ID: 16736689
    [No Abstract]   [Full Text] [Related]  

  • 18. Exforge HCT.
    Med Lett Drugs Ther; 2009 Jun; 51(1314):47. PubMed ID: 19528888
    [No Abstract]   [Full Text] [Related]  

  • 19. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birth.
    Bos-Thompson MA; Hillaire-Buys D; Muller F; Dechaud H; Mazurier E; Boulot P; Morin D
    Ann Pharmacother; 2005 Jan; 39(1):157-61. PubMed ID: 15590878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VALUE: analysis of results.
    Sever P
    Lancet; 2004 Sep 11-17; 364(9438):933-4; author reply 935. PubMed ID: 15364180
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.